# Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

> **NCT07710534** · PHASE2 · RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed / Refractory AML
- High Risk Myelodysplastic Syndrome
- High Risk Myeloproliferative Neoplasms

## Interventions

- **DRUG:** Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)
- **DRUG:** Azacitidine plus venetoclax (AZA+VEN)

## Key facts

- **NCT ID:** NCT07710534
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-16
- **Primary completion:** 2031-09-30
- **Final completion:** 2033-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710534, "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*